The management of clinically localized renal cell carcinoma (RCC) has been grounded in surgical extirpation for many decades now, and remains the only consistent approach to offer a cure for patients with this disease. For many years, therapy for advanced disease had been frustrated by its resistance to conventional cytotoxic chemotherapy. Cytokine-based approaches formed the mainstay of our armamentarium and offered response rates on the order of 10-20%, with modest improvements in survival and long-term disease-free survival in less than 5%. Clearly, new approaches were needed. Within the last several years, new advances have begun to revolutionize the management of advanced RCC and offer hope where before the outlook was often bleak. These included a more accurate and proven role for aggressive surgical resection of the primary lesion and, in selected cases, metastectomy as well as refinements in cytokine-based therapy. In carefully selected patients, the possibility of allogeneic, hematopoietic, stem-cell transplantation has been explored. The ability to risk stratify patients accurately has substantially improved and current approaches to the molecular classification of renal neoplasms offer newfound opportunities, not only in predicting an individual person's prognosis, but also potential new targets for therapy. It is not too farfetched to envision, in the not-so-distant future, individualized, targeted therapy based on the molecular defects in an individual's particular tumor. Perhaps the most profound change, however, has come out of the work on the molecular biology of RCC. In particular, the elucidation of the central role played by aberrations of the von Hippel Lindau gene/protein and its downstream consequences in clear cell (conventional) carcinoma. These insights have led to a series of exciting new approaches, so-called "Targeted Therapy", that have revolutionized how we approach advanced RCC. The articles in this special issue will address many of these changing paradigms in the management of RCC, and highlight how far we have come and how far we still need to go. The war against RCC has not been won yet, but as a research and therapeutic community, we are starting to win some of the smaller battles, one at a time. The key to future progress depends on an ongoing commitment to enrollment in carefully designed and executed clinical trials, the courage of the patients who participate in them, and continued dedication on the part of clinicians and scientists who work on this difficult and challenging disease. 
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